Literature DB >> 16422994

Review article: non-biological liver support in liver failure.

W Laleman1, A Wilmer, P Evenepoel, C Verslype, J Fevery, F Nevens.   

Abstract

Liver failure, whether acute or acute-on-chronic, remains an important cause of morbidity and mortality. The lack of liver detoxification, metabolic and regulatory functions of the liver leads to life-threatening complications, such as renal failure, altered immune response, hepatic coma and systemic haemodynamic dysfunction, eventually culminating in multiorgan failure. Current medical therapy involves the management of the precipitating event and treatment of complications until the liver eventually recovers, leaving us with no other treatment options than transplantation if these attempts fail. However, the shortage in cadaveric organs and other transplant-related problems, have prompted the need for alternative methods to provide liver support. As liver failure is often potentially reversible, considerable effort has been invested in the development of liver support systems. Currently, most of the experience is available for non-biological support systems. They represent the focus of this review, which aims to define the goals of liver support, to describe the design of the different existing devices and to analyse the available data to determine their current status in the management of patients with liver failure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16422994     DOI: 10.1111/j.1365-2036.2006.02765.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  11 in total

1.  Short-term efficacy of treating hepatitis B virus-related acute-on-chronic liver failure based on cold pattern differentiation with hot herbs: A randomized controlled trial.

Authors:  Yu-Ming Guo; Feng-Yi Li; Man Gong; Lin Zhang; Jia-Bo Wang; Xiao-He Xiao; Jun Li; Yan-Ling Zhao; Li-Fu Wang; Xiao-Feng Zhang
Journal:  Chin J Integr Med       Date:  2016-05-24       Impact factor: 1.978

Review 2.  Definition of ACLF and inclusion criteria for extra-hepatic organ failure.

Authors:  Xiaojing Wang; Shiv Kumar Sarin; Qin Ning
Journal:  Hepatol Int       Date:  2015-05-28       Impact factor: 6.047

3.  Effect evaluation of interleukin-1 receptor antagonist nanoparticles for mesenchymal stem cell transplantation.

Authors:  Xiao-Lei Shi; Wei Zhu; Jia-Jun Tan; Jiang-Qiang Xiao; Lin Zhang; Qian Xu; Zheng-Liang Ma; Yi-Tao Ding
Journal:  World J Gastroenterol       Date:  2013-03-28       Impact factor: 5.742

Review 4.  Bench-to-beside review: acute-on-chronic liver failure - linking the gut, liver and systemic circulation.

Authors:  Len Verbeke; Frederik Nevens; Wim Laleman
Journal:  Crit Care       Date:  2011-10-25       Impact factor: 9.097

5.  A prospective randomized open-label crossover trial of regional citrate anticoagulation vs. anticoagulation free liver dialysis by the Molecular Adsorbents Recirculating System.

Authors:  Björn Meijers; Wim Laleman; Pieter Vermeersch; Frederik Nevens; Alexander Wilmer; Pieter Evenepoel
Journal:  Crit Care       Date:  2012-02-03       Impact factor: 9.097

6.  Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure.

Authors:  Wim Laleman; Alexander Wilmer; Pieter Evenepoel; Ingrid Vander Elst; Marcel Zeegers; Zahur Zaman; Chris Verslype; Johan Fevery; Frederik Nevens
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

Review 7.  Acute-on-chronic liver failure: a review.

Authors:  Luis Eduardo Zamora Nava; Jonathan Aguirre Valadez; Norberto C Chávez-Tapia; Aldo Torre
Journal:  Ther Clin Risk Manag       Date:  2014-04-23       Impact factor: 2.423

8.  Modifying three-dimensional scaffolds from novel nanocomposite materials using dissolvable porogen particles for use in liver tissue engineering.

Authors:  Hussamuddin Adwan; Barry Fuller; Clare Seldon; Brian Davidson; Alexander Seifalian
Journal:  J Biomater Appl       Date:  2012-04-24       Impact factor: 2.646

9.  Liver myofibroblasts from hepatitis B related liver failure patients may regulate natural killer cell function via PGE2.

Authors:  Min Zhang; Fenglan Wang; Yutian Chong; Qiang Tai; Qiyi Zhao; Yubao Zheng; Liang Peng; Shumei Lin; Zhiliang Gao
Journal:  J Transl Med       Date:  2014-11-04       Impact factor: 5.531

10.  Clinical effectiveness of MARS treatment - multidirectional analysis of positive clinical response to treatment.

Authors:  Wojciech Mielnicki; Agnieszka Dyla; Maciej Karczewski
Journal:  Clin Exp Hepatol       Date:  2019-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.